Japanese  
  Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Vanderbilt Study Finds Diverse Genetic… >
Vanderbilt Study Finds Diverse Genetic Alterations in Triple-negative Breast Cancers

Published: December 7, 2012.
By Vanderbilt University Medical Center
http://www.mc.vanderbilt.edu/npa

Most triple-negative breast cancer patients who were treated with chemotherapy to shrink the tumor prior to surgery still had multiple genetic mutations in their tumor cells, according to a study by Vanderbilt-Ingram Cancer Center (VICC) investigators.

Finding multiple mutations instead of just one primary mutation that can be targeted for therapy sheds more light on the challenges of treating triple-negative breast cancer.

The study, led by Justin Balko, Pharm.D., Ph.D., and research faculty in the laboratory of Carlos Arteaga, M.D., director of the Breast Cancer Program at VICC, was presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 4-8.

Approximately 15 percent of breast cancer patients in the U.S. have triple-negative cancer – a form of the disease that disproportionately affects young African-American women. Triple-negative breast cancer has traditionally been more difficult to treat than other forms of the disease.

"The standard of care for many patients with triple-negative breast cancer is to administer chemotherapy before surgery to shrink the tumor," Balko said. "Unfortunately, about 70 percent of patients still have some residual disease at the time of surgery, despite treatment."

Balko and colleagues profiled residual tumor tissue from 114 patients with triple-negative breast cancer who had received chemotherapy prior to surgery. Triple-negative breast cancer cells do not have estrogen receptors, progesterone receptors, or large amounts of the HER2/neu protein.

The investigators were able to evaluate DNA from 81 tumors and used deep sequencing to examine 182 oncogenes and tumor suppressors that are known to be altered in human cancers. Instead of finding similar genes affected among the patients, they found a diverse set of genes were altered.

"We already knew that triple-negative breast cancer is driven by a diverse group of genetic alterations," Balko said. "So, in one way, we fell further down this rabbit hole, but we also found some things that could be promising therapeutically, such as frequent MYC, MCL1 and JAK2 amplifications as well as mutations in the PI3K pathway."

The additional genetic alterations found in the study may provide targets for new therapies.

Balko said the next step is to confirm the findings in a larger patient group, and if the findings are replicated, broad molecular approaches will be needed to help develop personalized therapies for triple-negative breast cancer. It also will be necessary to explore the therapeutic sensitivity of breast cancers harboring these lesions in the laboratory to know how to treat patients who have these alterations.


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Treatment 
3/19/12 
Breaking the Backbone of Triple-negative Breast Cancers
By Rockefeller University Press
Putting the brakes on an abundant growth-promoting protein causes breast tumors to regress, according to a study published on March 19th in the Journal of Experimental Medicine. …
Breast 
2/28/13 
Groundbreaking UK Study Shows Key Enzyme Missing from Aggressive Form of Breast Cancer
By University of Kentucky
LEXINGTON, Ky. (Feb. 28, 2013) – A groundbreaking new study led by the University of Kentucky Markey Cancer Center's Dr. Peter Zhou found that triple-negative breast cancer cells are …
Cancer 
2/7/13 
Triple-negative Breast Cancer Subtypes Identified Using MicroRNA
By Ohio State University Medical Center
COLUMBUS, Ohio – A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy. …
Breast 
11/12/12 
PI3-kinase And PARP Inhibitor Combo May Offer New Treatment Option for Triple-neg Breast Cancers
By American Association for Cancer Research
PHILADELPHIA — The simultaneous inhibition of two separate and seemingly unrelated pathways could potentially provide an effective treatment for women with triple-negative breast cancer, according to results of two …
Stem 
2/17/14 

New Finding Points to Potential Options for Attacking Stem Cells in Triple-negative Breast Cancer
By University of Michigan Health System
Breast 
2/13/13 
★★★ 
Copper Depletion Therapy Keeps High-risk Triple-negative Breast Cancer at Bay
By Weill Cornell Medical College
NEW YORK (February 13, 2013) -- An anti-copper drug compound that disables the ability of bone marrow cells from setting up a "home" in organs to receive and nurture …
Breast 
9/28/10 
Triple-negative Breast Cancers May Have Unique Therapeutic Target
By American Association for Cancer Research
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according …
More » 
 
ScienceNewsline  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition
The selection and placement of stories are determined automatically by a computer program. All contents are copyright of their owners except U.S. Government works. U.S. Government works are assumed to be in the public domain unless otherwise noted. Everything else copyright ScienceNewsline.